Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Intravenous (IV) Ibuprofen Market Forecast: Value Set To Climb From $10.51 Billion To $16.41 Billion
The market size for intravenous (iv) ibuprofen has experienced substantial expansion in recent years. It is anticipated to grow from $9.37 billion in 2025 to $10.51 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.1%. The growth observed in the past can be ascribed to an increasing need for postoperative pain management, the extensive adoption of NSAIDs in hospital settings, a rise in the volume of surgical procedures, the escalating occurrence of acute inflammatory conditions, and the established clinical effectiveness of ibuprofen for managing both pain and fever.
The market for intravenous (iv) ibuprofen is projected to experience substantial expansion over the upcoming years, with its size anticipated to reach $16.41 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.8%. This growth during the forecast period is expected to stem from a rising demand for pain management strategies that conserve opioids, an increasing integration of iv therapies within ambulatory surgical centers, elevated hospitalization rates among pediatric and geriatric populations, the ongoing expansion of acute care infrastructure, and an escalating preference for analgesic treatments that provide rapid onset. Prominent trends throughout this period are set to include a broader adoption of iv ibuprofen for managing postoperative pain, a greater utilization of non-opioid analgesics in acute care environments, an increasing inclination towards fast-acting injectable pain therapies, the expansion of iv ibuprofen’s application in both pediatric and critical care, and an increasing supply of high-concentration iv ibuprofen formulations.
Get A Free Sample Report With In-Depth Market Insights:
Intravenous (IV) Ibuprofen Market Demand Drivers: What’s Powering Industry Growth?
An anticipated increase in the intravenous ibuprofen market’s expansion is linked to the growing occurrence of pain disorders. These conditions are defined as health issues marked by enduring or long-lasting pain impacting daily activities, frequently stemming from problems with nerves, muscles and bones, or inflammation. The heightened incidence of pain disorders is attributed to the aging demographic, given that elderly individuals are more susceptible to developing chronic ailments such as arthritis, osteoarthritis, and nerve pain, thereby raising the demand for efficient pain management. Intravenous ibuprofen aids in pain control by delivering rapid alleviation, rendering it suitable for intense and post-surgical pain. It lessens inflammation and boosts patient well-being, thus enhancing the efficacy of treatment within healthcare environments. As an illustration, in January 2024, data from the Office for Health Improvement and Disparities, a UK-based government department, indicated that the proportion of individuals aged 16 and older who reported a long-term musculoskeletal condition themselves climbed to 18.4% in 2023, an increase from 17.6% in 2022. Consequently, the increased occurrence of pain disorders is fueling the expansion of the intravenous ibuprofen market.
Intravenous (IV) Ibuprofen Market Segment Performance And Emerging Opportunities
The intravenous (iv) ibuprofen market covered in this report is segmented –
1) By Product Type: Conventional Intravenous (IV) Ibuprofen, High-Concentration Intravenous (IV) Ibuprofen
2) By Strength: 100 Milligrams (mg), 200 Milligrams (mg), 400 Milligrams (mg), 800 Milligrams (mg)
3) By Age Group: Pediatrics, Adults
4) By Application: Pain, Fever, Inflammation, Other Applications
5) By End-User: Hospitals, Ambulatory Surgical Centers, Clinics, Other End-Users
Subsegments:
1) By Conventional Intravenous (IV) Ibuprofen: Pediatric Intravenous (IV) Ibuprofen, Adult Intravenous (IV) Ibuprofen
2) By High-Concentration Intravenous (IV) Ibuprofen: Single-Dose Vial, Multi-Dose Vial
Intravenous (IV) Ibuprofen Market Innovation Trends: What Developments Are Reshaping The Industry?
Major companies within the intravenous ibuprofen market are prioritizing the development of sophisticated drug formulations, particularly opioid-free analgesics, to optimize pain management while minimizing reliance on opioids. An opioid-free analgesic is a pain-relieving medication devoid of opioids, thereby eliminating the risk of addiction and opioid-related adverse effects. For example, in February 2024, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, rolled out COMBOGESIC IV (acetaminophen and ibuprofen) injection in the US, following its Food and Drug Administration (FDA) approval in October 2023. This intravenous, opioid-free analgesic is intended for alleviating mild to moderate pain and serving as an auxiliary treatment for moderate to severe pain management. By merging two active components with different mechanisms of action, COMBOGESIC IV presents a fresh, non-opioid pain management solution for medical professionals.
Intravenous (IV) Ibuprofen Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the intravenous (iv) ibuprofen market are Pfizer Inc., Sanofi S.A., Novartis AG, Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., Baxter International, Mylan N.V., Sandoz Group AG, Dr. Reddy’s Laboratories, Hikma Pharmaceuticals plc, Eurolife Healthcare Pvt. Ltd., B. Braun Holding GmbH & Co. KG, AFT Pharmaceuticals Ltd, Cumberland Pharmaceuticals Inc., Delex Pharma International Inc., Xgen Pharmaceuticals Djb Inc., Wellona Pharma, Hyloris Pharmaceuticals SA
View The Full Intravenous (IV) Ibuprofen Market Report:
Intravenous (IV) Ibuprofen Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the intravenous (IV) ibuprofen market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous (iv) ibuprofen market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
